Antibacterial drug discovery & development summit

Expert Opinion on Investigational Drugs

Volumn 13, Issue 6, 2004, Pages 715-721

  Barrett, John F ^a   Dougherty, Thomas J ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antibacterial; Antibiotic; Genomics; Pipeline; Resistance emergence; Targets

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; DORIPENEM; ERYTHROMYCIN; GARENOXACIN; GENTAMICIN; KETOLIDE; LINEZOLID; MACROLIDE; METAL DERIVATIVE; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAMOPLANIN; TEICOPLANIN; TELITHROMYCIN; TETRACYCLINE; TIGECYCLINE; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIOPHAGE TYPING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HEMOLYTIC ANEMIA; HUMAN; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MYOPATHY; NONHUMAN; PRURITUS; QT PROLONGATION; RIBOSOME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; HUMANS; RESEARCH;

EID: 3042727168     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.6.715     Document Type: Conference Paper

References (0)